TrialsgrambetaRCTs are beautiful

Tuberculosis

3 trials
  • 2022TB-PRACTECALMDR-TBIn 552 patients with rifampicin-resistant tuberculosis, a 24-week regimen of bedaquiline, pretomanid, linezolid and moxifloxacin improved favourable outcome at 72 weeks compared with the 9–20-month standard of care.
  • 2022ZeNixMDR/XDR-TBIn 181 patients with MDR or XDR tuberculosis, BPaL with linezolid 600 mg for 26 weeks preserved favourable outcome while reducing toxicity compared with linezolid 1200 mg for 26 weeks.
  • 2021Study 31 / A5349Drug-susceptible TBIn 2,516 patients with drug-susceptible pulmonary tuberculosis, a 4-month regimen of high-dose rifapentine plus moxifloxacin was non-inferior to the standard 6-month regimen for TB-free survival.